Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCALA phase 2 trial of galvokimig in moderate-to-severe COPD with chronic bronchitis
CTR20262955Phase 2Active
- Sponsor
- UCB
- Start
- Aug 2026
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of galvokimig in chronic obstructive pulmonary disease (COPD), chronic bronchitis (CB), sponsored by UCB. Started Aug 2026; status: active.
02
Drugs
galvokimig
03
Conditions
chronic obstructive pulmonary disease (COPD)chronic bronchitis (CB)
Beyond the preview
Go deeper on CTR20262955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262955.